Elena Baldissera Selected Research

Elena Baldissera Research Topics

Disease

12	Takayasu Arteritis (Arteritis, Takayasu's) 10/2023 - 10/2011
7	Inflammation (Inflammations) 12/2020 - 01/2009
6	Adult-Onset Still's Disease 01/2020 - 08/2010
4	Rheumatoid Arthritis 01/2020 - 06/2006
2	Vasculitis (Vasculitides) 01/2023 - 08/2015
2	Arteritis 01/2017 - 11/2014
2	Arthritis (Polyarthritis) 09/2015 - 08/2010
1	Psoriasis (Pustulosis Palmaris et Plantaris) 03/2024
1	Neoplasms (Cancer) 03/2024
1	Giant Cell Arteritis (Horton Disease) 01/2023
1	COVID-19 01/2020
1	Mycoses (Diseases, Fungus) 01/2020
1	Immunoglobulin G4-Related Disease 01/2020
1	Exanthema (Rash) 01/2019
1	Atherosclerosis 02/2018
1	Cardiomyopathies (Cardiomyopathy) 02/2018
1	Microvascular Angina (Cardiac Syndrome X) 02/2018
1	Hypertension (High Blood Pressure) 01/2016
1	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 08/2015
1	Microscopic Polyangiitis 08/2015
1	Granulomatosis with Polyangiitis (Wegener's Granulomatosis) 08/2015
1	Systemic Scleroderma (Systemic Sclerosis) 03/2014
1	Fibrosis (Cirrhosis) 03/2014
1	Pulmonary Hypertension 03/2014
1	Sclerosis 03/2014
1	Amenorrhea 12/2013
1	Stable Angina 01/2012
1	Bone Fractures (Bone Fracture) 01/2012
1	Myocardial Infarction 01/2012
1	Acute Coronary Syndrome 01/2012
1	Autoimmune Diseases (Autoimmune Disease) 01/2012
1	Systemic Vasculitis 01/2012
1	Sepsis (Septicemia) 01/2012
1	Latent Tuberculosis 10/2010
1	Tuberculosis (Tuberculoses) 10/2010

Drug/Important Bio-Agent (IBA)

5	tocilizumab (atlizumab)FDA Link 01/2023 - 12/2013
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2020 - 06/2006
3	Interleukin-1 (Interleukin 1)IBA 12/2020 - 01/2017
3	Interleukin-6 (Interleukin 6)IBA 12/2020 - 08/2015
3	C-Reactive ProteinIBA 01/2017 - 10/2011
2	Monoclonal AntibodiesIBA 03/2024 - 01/2020
2	Rituximab (Mabthera)FDA Link 10/2023 - 01/2020
2	SteroidsIBA 01/2023 - 08/2010
2	Infliximab (Remicade)FDA Link 02/2022 - 01/2021
2	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 01/2020 - 01/2019
2	canakinumab FDA Link 02/2019 - 01/2019
2	Chromogranin AIBA 01/2016 - 01/2009
2	Biomarkers (Surrogate Marker)IBA 11/2014 - 10/2011
1	secukinumabIBA 03/2024
1	Interleukin-17 (Interleukin 17)IBA 03/2024
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2023
1	SuspensionsIBA 01/2023
1	Methotrexate (Mexate)FDA LinkGeneric 01/2023
1	Biosimilar PharmaceuticalsIBA 01/2021
1	EpitopesIBA 01/2020
1	GlucocorticoidsIBA 01/2020
1	Antirheumatic Agents (DMARD)IBA 01/2020
1	Sympathomimetics (Sympathomimetic Amines)IBA 02/2018
1	InterleukinsIBA 01/2017
1	Peptides (Polypeptides)IBA 01/2016
1	Proton Pump InhibitorsIBA 01/2016
1	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 08/2015
1	Contrast MediaIBA 11/2014
1	Pattern Recognition ReceptorsIBA 11/2014
1	ProcalcitoninIBA 07/2014
1	IntegrinsIBA 03/2014
1	Reactive Oxygen Species (Oxygen Radicals)IBA 03/2014
1	HMGB1 Protein (HMG1)IBA 03/2014
1	CytokinesIBA 02/2014
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2013
1	gadofosveset trisodium (MS 325)FDA Link 03/2012
1	Peroxidase (Myeloperoxidase)IBA 01/2012
1	P-SelectinIBA 01/2012
1	Tuberculin (PPD)IBA 10/2010
1	Immunosuppressive Agents (Immunosuppressants)IBA 08/2010
1	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 08/2010

Therapy/Procedure

4	Therapeutics 01/2023 - 08/2010
1	Duration of Therapy 01/2020
1	Remission Induction 01/2020